Clinical trial
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate…
NCT00307541 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00307541 |
|---|---|
| Title | Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine |
| Official title | Phase IIIa Randomized, Controlled Study to Assess the Immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered as a 3-dose Primary Immunization Course Before 6 Months of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Streptococcal, Streptococcus Pneumoniae Vaccines |
| Intervention type | Biological |
| Interventions | Pneumococcal (vaccine) |
| Enrollment | 120 |
| Start date | Oct 27, 2005 |
| Primary completion | Apr 7, 2006 |
| Completion | Apr 7, 2006 |
| First posted | Mar 28, 2006 |
| Last update posted | Jan 2, 2020 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: